Liu, Y., Clarke, J. M., Starr, M. D., Brady, J. C., Pang, H., Rushing, C., … Nixon, A. B. (2014). Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial. In Journal of Clinical Oncology (Vol. 32, pp. 11020–11020). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.11020

Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.

Liu Y, Clarke JM, Starr MD, Brady JC, Pang H, Rushing C, et al. Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 11020–11020.

Liu, Yingmiao, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 11020–11020. Crossref, doi:10.1200/jco.2014.32.15_suppl.11020.

Liu Y, Clarke JM, Starr MD, Brady JC, Pang H, Rushing C, Alvarez D, Adams BJ, Theuer CP, Hurwitz H, Nixon AB. Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 11020–11020.